Pamapimod（R-1503,Ro4402257),p38 inhibitor

Pamapimod（R-1503,Ro4402257),p38 inhibitor

Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.

Product name: Pamapimod（R-1503）|Purity>98%| CAS: 449811-01-2|Molecule Formular: C19H20F2N4O4 |MW: 406.38 |Other Namess: Pamapimod; R 1503; R1503; R-1503; Ro 4402257; Ro4402257; Ro-4402257

Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.Pamapimod inhibited p38alpha and p38beta enzymatic activity, with IC(50) values of 0.014 +/- 0.002 and 0.48 +/- 0.04 microM, respectively. There was no activity against p38delta or p38gamma isoforms. When profiled across 350 kinases, pamapimod bound only to four kinases in addition to p38. Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH(2)-terminal kinase (JNK), respectively. Pamapimod inhibited p38 (IC(50), 0.06 microM), but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) alpha production by monocytes, interleukin (IL)-1beta production in human whole blood, and spontaneous TNFalpha production by synovial explants from RA patients. Pamapimod is a potent, selective inhibitor of p38alpha with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.

For research only, not for human use.